Total Payments
$833.41
2024 Payments
$320.42
Companies
14
Transactions
38
Medicare Patients
716
Medicare Billing
$78,555
Payment Breakdown by Category
Food & Beverage$833.41 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $833.41 | 38 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $144.83 | 4 | $0 (2024) |
| ABBVIE INC. | $115.00 | 6 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $81.73 | 5 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $72.52 | 2 | $0 (2023) |
| Lilly USA, LLC | $69.80 | 4 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $67.93 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $61.65 | 3 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $56.27 | 3 | $0 (2023) |
| GlaxoSmithKline, LLC. | $35.40 | 2 | $0 (2024) |
| MDD US Operations, LLC | $30.53 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $320.42 | 17 | AstraZeneca Pharmaceuticals LP ($81.73) |
| 2023 | $312.83 | 16 | AbbVie Inc. ($82.46) |
| 2022 | $60.68 | 2 | Neurocrine Biosciences, Inc. ($35.45) |
| 2021 | $87.64 | 1 | Novo Nordisk Inc ($87.64) |
| 2018 | $30.25 | 1 | Astellas Pharma US Inc ($30.25) |
| 2017 | $21.59 | 1 | GlaxoSmithKline, LLC. ($21.59) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: Oncology | ||||||
| 11/19/2024 | ACADIA Pharmaceuticals Inc | DAYBUE (Drug) | Food and Beverage | In-kind items and services | $33.14 | General |
| Category: RETT SYNDROME | ||||||
| 10/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: RESPIRATORY | ||||||
| 10/09/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Diabetes | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: Respiratory | ||||||
| 07/16/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Respiratory | ||||||
| 07/10/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Diabetes | ||||||
| 04/25/2024 | ACADIA Pharmaceuticals Inc | DAYBUE (Drug) | Food and Beverage | In-kind items and services | $34.79 | General |
| Category: RETT SYNDROME | ||||||
| 04/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/10/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: NEUROSCIENCE | ||||||
| 04/04/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $24.55 | General |
| Category: Diabetes | ||||||
| 03/27/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/27/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Respiratory | ||||||
| 01/18/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: Diabetes | ||||||
| 01/17/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: NEUROSCIENCE | ||||||
| 01/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/26/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Diabetes | ||||||
| 10/24/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $23.21 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/21/2023 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: Central Nervous System | ||||||
| 06/29/2023 | Lilly USA, LLC | EMGALITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: Neuroscience | ||||||
| 06/20/2023 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: Oncology | ||||||
| 06/01/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: NEUROSCIENCE | ||||||
| 05/04/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Iron Deficiency Anemia | ||||||
| 05/03/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 556 | 736 | $211,317 | $59,250 |
| 2022 | 5 | 160 | 181 | $68,246 | $19,305 |
Total Patients
716
Total Services
917
Medicare Billing
$78,555
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 123 | 228 | $72,551 | $19,956 | 27.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 119 | 178 | $38,959 | $11,584 | 29.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 61 | 61 | $20,724 | $7,538 | 36.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 78 | 78 | $37,522 | $7,485 | 19.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $26,386 | $4,555 | 17.3% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 15 | 15 | $4,800 | $4,243 | 88.4% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 16 | 16 | $1,344 | $1,213 | 90.3% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 15 | 15 | $3,786 | $902.39 | 23.8% |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | Office | 2023 | 16 | 16 | $2,944 | $595.15 | 20.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 19 | 19 | $475.00 | $465.50 | 98.0% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 15 | 15 | $720.00 | $442.65 | 61.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 21 | $896.00 | $204.63 | 22.8% |
| 81003 | Automated urinalysis test | Office | 2023 | 22 | 30 | $210.00 | $66.00 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 54 | 74 | $23,606 | $6,830 | 28.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 44 | 44 | $21,252 | $5,496 | 25.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 29 | 29 | $17,632 | $4,606 | 26.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 22 | $4,796 | $1,529 | 31.9% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 12 | 12 | $960.00 | $843.00 | 87.8% |
About Dr. Laura Teveni, M.D
Dr. Laura Teveni, M.D is a Family Medicine healthcare provider based in Electra, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2015. The National Provider Identifier (NPI) number assigned to this provider is 1871972588.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Laura Teveni, M.D has received a total of $833.41 in payments from pharmaceutical and medical device companies, with $320.42 received in 2024. These payments were reported across 38 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($833.41).
As a Medicare-enrolled provider, Teveni has provided services to 716 Medicare beneficiaries, totaling 917 services with total Medicare billing of $78,555. Data is available for 2 years (2022–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Electra, TX
- Active Since 05/27/2015
- Last Updated 08/03/2018
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1871972588
Products in Payments
- RYBELSUS (Drug) $87.64
- Ongentys (Drug) $72.52
- UBRELVY (Drug) $67.96
- DAYBUE (Drug) $67.93
- AIRSUPRA (Drug) $66.06
- Rybelsus (Drug) $57.19
- MOUNJARO (Drug) $47.64
- QULIPTA (Drug) $47.04
- LEQVIO (Drug) $38.44
- GOCOVRI (Drug) $30.53
- MYRBETRIQ (Drug) $30.25
- Cologuard Collection Kit (Device) $28.93
- AJOVY (Biological) $25.23
- INJECTAFER (Drug) $23.76
- ENTRESTO (Drug) $23.21
- EMGALITY (Drug) $22.16
- ANORO ELLIPTA (Drug) $21.59
- AUSTEDO (Drug) $17.36
- FARXIGA (Drug) $15.67
- Trudhesa (Drug) $14.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.